Relapse versus reinfection: Recurrent clostridium difficile infection following treatment with fidaxomicin or vancomycin

Clinical Infectious Diseases

Volumn 55, Issue SUPPL.2, 2012, Pages

  Figueroa, Iris ^a   Johnson, Stuart ^a,b   Sambol, Susan P ^a,b   Goldstein, Ellie J C ^c,d   Citron, Diane M ^c   Gerding, Dale N ^a,b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c RM Alden Research Laboratory ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FECES CULTURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; REINFECTION; RELAPSE; RESTRICTION MAPPING; RISK ASSESSMENT;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL TYPING TECHNIQUES; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DNA, BACTERIAL; ENTEROTOXINS; EUROPE; FECES; HUMANS; MIDDLE AGED; RECURRENCE; TIME FACTORS; UNITED STATES; VANCOMYCIN;

EID: 84863661973     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis357     Document Type: Article

References (15)

1. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-10.
2. Pepin J, Alary ME, Valiquette L. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7. (Pubitemid 40720808)
3. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159:340-3. (Pubitemid 19049377)
4. O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991; 107:627-35.
5. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998; 38:93-100. (Pubitemid 28143351)
6. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficileassociated diarrhea. J Clin Microbiol 2000; 38:2386-8. (Pubitemid 30414372)
7. Tang-Feldman Y, Mayo S, Silva J Jr, Cohen SH. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. Clin Microbiol 2003; 41: 3413-4. (Pubitemid 36842364)
8. Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
9. Crook D, Weiss K, Cornely O, et al. Randomized clinical trial (RCT) in Clostridium difficile infection (CDI) confirms equivalent cure rate and lower recurrence rate of fidaxomicin (FDX) versus vancomycin (VCN). Presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 April 2010; Vienna, Austria. Abstract LB2401.
10. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993; 31:1870-5. (Pubitemid 23182592)
11. Killgore G, Thompson A, Johnson S, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variablenumber tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008; 46:431-7. (Pubitemid 351231282)
12. Belmares J, Johnson S, Parada JP, et al. Molecular epidemiology of Clostridium difficile over 10 years in a tertiary care hospital. Clin Infect Dis 2009; 49:1141-7.
13. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341:1645-51.
14. NDA 201,699. 12.4: Mechanism of decreased susceptibility to fidaxomicin: In: Dificid™ [prescribing Information]. San Diego, California: Optimer Pharmaceuticals, Inc, 2011:9.
15. Petrella LR, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain [published online ahead of print 21 May 2012]. Clin Infect Dis 2012.